4581 Stock Overview
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Taisho Pharmaceutical Holdings Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥8,580.00 |
52 Week High | JP¥8,753.00 |
52 Week Low | JP¥5,150.00 |
Beta | 0.50 |
1 Month Change | -0.035% |
3 Month Change | -0.44% |
1 Year Change | 50.00% |
3 Year Change | 28.06% |
5 Year Change | -14.11% |
Change since IPO | 27.11% |
Recent News & Updates
Recent updates
Shareholder Returns
4581 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | -0.1% | -3.0% | -4.7% |
1Y | 50.0% | 2.7% | 26.3% |
Return vs Industry: 4581 exceeded the JP Pharmaceuticals industry which returned 6.3% over the past year.
Return vs Market: 4581 exceeded the JP Market which returned 33.8% over the past year.
Price Volatility
4581 volatility | |
---|---|
4581 Average Weekly Movement | 0.3% |
Pharmaceuticals Industry Average Movement | 3.7% |
Market Average Movement | 4.1% |
10% most volatile stocks in JP Market | 8.2% |
10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4581 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4581's weekly volatility (0%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1912 | 8,784 | Akira Uehara | www.taisho-holdings.co.jp |
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The company offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops.
Taisho Pharmaceutical Holdings Co., Ltd. Fundamentals Summary
4581 fundamental statistics | |
---|---|
Market cap | JP¥703.28b |
Earnings (TTM) | JP¥8.42b |
Revenue (TTM) | JP¥320.39b |
83.5x
P/E Ratio2.2x
P/S RatioIs 4581 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4581 income statement (TTM) | |
---|---|
Revenue | JP¥320.39b |
Cost of Revenue | JP¥137.22b |
Gross Profit | JP¥183.17b |
Other Expenses | JP¥174.74b |
Earnings | JP¥8.42b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 102.74 |
Gross Margin | 57.17% |
Net Profit Margin | 2.63% |
Debt/Equity Ratio | 0% |
How did 4581 perform over the long term?
See historical performance and comparison